Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Puma Biotechnology Inc    PBYI   US74587V1070

News SummaryMost relevantAll newsSector news 

Puma Biotechnology : PBYI) Drops 5% on August 21

08/22/2014 | 11:23am US/Eastern

Puma Biotechnology Inc (PBYI) was one of the Russell 2000's biggest losers for August 21 as the stock slid 5% to $237.41, a loss of $12.5 per share. Starting at an opening price of $250.12 a share, the stock traded between $234.62 and $251.88 over the course of the trading day. Volume was 417,667 shares over 4,418 trades. The company has a total float of 30,117,819.

The losses send Puma Biotechnology Inc down to a market cap of $7,150,271,409

For a full analysis of Puma Biotechnology Inc, check out's E.V.A. report.

One of the most effective tools for tracking the market for small-cap stocks is the Russell 2000, the nation's leading small-cap index created by industry stalwart Russell Investments. Unlike the well-known Dow Jones Industrial Average (DJIA) and S&P 500, Russell's indices eschew committee selection in favor of a more objective, rules-based system for selecting index membership.

The broad-based Russell 3000, which is meant to cover the stock market as a whole, is simply the 3,000 companies with the largest market cap in the United States. The Russell 2000 is then just the bottom 2,000 companies of that index, offering a look at those small-cap companies with smaller market caps. It makes for an unbiased overview of the small-cap stocks that can help any investor get a better sense of what the market is doing and where it might be headed.

For more news on the financial markets, go to Also, learn more about our Small-Cap Stars. Register to become a member and leverage our proprietary research tools such as the Small-Cap Stars, and robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports.

All data provided by QuoteMedia and was accurate as of 4.30PM.

Copyright All rights reserved.

React to this article
04/22 PUMA BIOTECHNOLOGY : Expands Cohort in Phase II Trial of PB272 in HER2 Mutation ..
04/17 PUMA BIOTECHNOLOGY : Bolsters Cohort in Phase II Trial of PB272
04/14 PUMA BIOTECHNOLOGY : Other Events, Financial Statements and Exhibits (form 8-K)
04/14 PUMA BIOTECHNOLOGY : Expands Cohort in Phase II Trial of PB272 in HER2 Mutation ..
03/30 PUMA BIOTECHNOLOGY : NYSE stocks posting largest percentage increases
03/18 PUMA BIOTECHNOLOGY : Initiates Phase II Trial of PB272 in Early Stage HER2-Posit..
03/12 PUMA BIOTECHNOLOGY : begins Phase II trial of breast cancer drug neratinib
03/11 PUMA BIOTECHNOLOGY : Reports Fourth Quarter and Full Year 2014 Financial Results
03/10 PUMA BIOTECHNOLOGY : Other Events, Financial Statements and Exhibits (form 8-K)
03/10 PUMA BIOTECHNOLOGY : to Present at Cowen Health Care Conference
Duration : Period :
Puma Biotechnology Inc Technical Analysis Chart | PBYI | US74587V1070 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes